The FDA has approved the first generic versions of Risperdal (risperidone) tablets, manufactured by Teva.
Filed under: gpcr | Tagged: agonsit, Approval, D2, Dopamine D2, Generic, regulatory, risperdal, risperidone | Leave a Comment »
Palatin and AstraZeneca amend melanocortin receptor research collaboration
Posted on July 1, 2008 by crimsoncanary
Palatin and AstraZeneca have announced an amendment to their melanocortin receptor research collaboration initiated in January 2007. Under the new terms Palatin will license additional compounds and associated intellectual property to AstraZeneca, receiving development and regulatory milestone payments.
Filed under: gpcr | Tagged: agonist, Astrazeneca, Licensing, Melanocortin, Palatin | Leave a Comment »
NuPathe report Phase I results with transdermal sumatriptan product NP101
Posted on July 1, 2008 by crimsoncanary
Phase I Data Presented at the American Headache Society meeting show NuPathe’s transdermal sumatriptan product NP101 to demonstrate efficacy in the treatment of migraine. The drug was well tolerated and adverse events for NP101 were generally mild
Filed under: gpcr | Tagged: 5-HT1D, 5HT1D, antagonist, formulation, NP-101, NP101, NuPathe, phase I, Sumatriptan | Leave a Comment »
deCODEs EP3 antagonist DG041 inhibits platelet aggregation without increasing bleeding time
Posted on July 1, 2008 by crimsoncanary
Phase II data announced by deCODE show its EP3 receptor antagonist DG-041 to inhibit platelet aggregation without increasing bleeding time
Filed under: Uncategorized | Tagged: antagonist, deCODE, DG-041, DG041, EP3, Prostaglandin EP3 | Leave a Comment »
